Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use USTEKINUMAB-TTWE safely and effectively. See full prescribing information for USTEKINUMAB-TTWE. USTEKINUMAB-TTWE injection, for subcutaneous or intravenous useInitial U.S. Approval: 2024 Ustekinumab-ttwe is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of USTEKINUMAB-TTWE has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information to STELARA (ustekinumab)
Medication labelWhy this: Advisory · dailymed-prescription
USTEKINUMAB-TTWE is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. USTEKINUMAB-TTWE is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. USTEKINUMAB-TTWE is indicated for the treatment of adult patients with moderately to severely active Crohn's disease. USTEKINUMAB-TTWE is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
- generic_name
- ustekinumab-ttwe
- product_names
- ustekinumab-ttwe
- ndc
- 82009-160, 82009-160-11, 82009-161, 82009-161-94, 82009-162, 82009-162-11, 82009-163, 82009-163-94
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en